Gene Biotherapeutics (Gene Biotherapeutics) Interest Expense : $-0.06 Mil (TTM As of Dec. 2020)

View and export this data going back to . Start your Free Trial

What is Gene Biotherapeutics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Gene Biotherapeutics's interest expense for the three months ended in Dec. 2020 was $ -0.01 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2020 was $-0.06 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Gene Biotherapeutics's Operating Income for the three months ended in Dec. 2020 was $ -0.48 Mil. Gene Biotherapeutics's Interest Expense for the three months ended in Dec. 2020 was $ -0.01 Mil. Gene Biotherapeutics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Gene Biotherapeutics Interest Expense Historical Data

The historical data trend for Gene Biotherapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gene Biotherapeutics Interest Expense Chart

Gene Biotherapeutics Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Interest Expense

Get a 7-Day Free Trial

-0.17

-0.02

-0.04

-0.06

Gene Biotherapeutics Quarterly Data
	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Dec17	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20
Interest Expense	Get a 7-Day Free Trial															-0.01	-0.02	-0.02	-0.01	-0.01

Gene Biotherapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.06 Mil.

Gene Biotherapeutics (OTCPK:CRXM) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Gene Biotherapeutics's Interest Expense for the three months ended in Dec. 2020 was $-0.01 Mil. Its Operating Income for the three months ended in Dec. 2020 was $-0.48 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2020 was $0.11 Mil.

Gene Biotherapeutics's Interest Coverage for the quarter that ended in Dec. 2020 is calculated as

Gene Biotherapeutics did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Gene Biotherapeutics (Gene Biotherapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gene Biotherapeutics Inc (OTCPK:CRXM) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

11230 Sorrento Valley Road, Suite 220, San Diego, CA, USA, 92121

Website

https://www.genebiotherapeutics.com

Gene Biotherapeutics Inc is a clinical stage biotechnology company focused on pre-clinical, clinical, and commercialization of angiogenic gene therapy biotherapeutics for strategic niche markets primarily for the treatment of cardiovascular disease. The company's lead product candidate Generx is an angiogenic gene therapy product candidate designed for medical revascularization for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease.

Executives

Andrew M Leitch	director	6615 CALLE PONTE BELLA, RANCHO SANTA FE CA 92091
Murray H Hutchison	director	C/O CADIZ INC., 550 SOUTH HOPE STREET, 2850, LOS ANGELES CA 90071
Dennis Mulroy	officer: Chief Financial Officer
Ronald I Simon	other: Former Director	485 MADISON AVENUE, 14TH FLOOR, NEW YORK NY 10022
Robert N Weingarten	director, officer: PRESIDENT and CFO	5439 LOCKHURST DRIVE, WOODLAND HILLS CA 91367

Gene Biotherapeutics (Gene Biotherapeutics) Headlines

From GuruFocus

Baron Funds Comments on CarMax Inc.

By Holly LaFon • 02-06-2013

Cardium Therapeutics Inc Reports Operating Results (10-Q)

By gurufocus 10qk • 05-10-2010

Gene Biotherapeutics Announces Sale Of Excellagen Technology Platform; Retains Commercialization Rights For Greater China And Russian Federation

By PRNewswire PRNewswire • 09-05-2018

Cardium Therapeutics Inc Reports Operating Results (10-Q)

By gurufocus 10qk • 11-09-2010